T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
- Details
- Category: Research
Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of COVID-19. The latest study by researchers at La Jolla Institute for Immunology clearly argues in favor of the immune system.
Designed antiviral proteins inhibit SARS-CoV-2 in the lab
- Details
- Category: Research
Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.
In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.
Progress toward antiviral treatments for COVID-19
- Details
- Category: Research
COVID-19 is caused by a virus known as SARS-CoV-2, which is similar in structure to two other viruses that have caused recent outbreaks: SARS-CoV, which caused an outbreak of SARS in 2003, and MERS-CoV, the cause of a 2012 outbreak of Middle East Respiratory Syndrome.
Tiny antibody component highly effective against SARS-COV-2 in animal studies
- Details
- Category: Research
University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug - known as Ab8 - for potential use as a therapeutic and prophylactic against SARS-CoV-2.
Which immune response could cause a vaccine against COVID-19?
- Details
- Category: Research
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition. It is especially important now when multiple vaccines against COVID-19 are being developed. The top immunologists analyse types of immune response to predict what kind of vaccine would be the best.
Genome analyses track SARS-CoV-2's early introduction to the US and Europe
- Details
- Category: Research
SARS-CoV-2 arrived in Washington State somewhere between late January and early February 2020, sparking rapid community transmission of the virus that went undetected for several weeks before this community spread became evident, prompting a change in testing criteria to emphasize individuals with no travel history. That's the scenario proposed by Trevor Bedford and colleagues after their analysis of the genetic sequences of 455 SARS-CoV-2 viruses from the Washington State outbreak collected between January 19 and March 15, 2020.
COVID-19 study links strict social distancing to much lower chance of infection
- Details
- Category: Research
Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive with the coronavirus SARS-CoV-2, while practicing strict social distancing is associated with a markedly lower likelihood, suggests a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
More Pharma News ...
- Small study shows convalescent plasma is safe to use in pediatric patients with COVID-19
- Preliminary results from Russian trials find that vaccine candidates led to no serious adverse events and elicit antibody response
- Vitamin D deficiency may raise risk of getting COVID-19
- Steroid found to improve survival of critically ill COVID-19 patients
- Improving FDA's COVID-19 vaccine authorization and approval process
- Antiviral used to treat cat coronavirus also works against SARS-CoV-2
- Search for COVID-19 drugs boosted by SARS discovery